Achilles Therapeutics plc (ACHL)
| Market Cap | 163.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.79M |
| Shares Out | 40.60M |
| EPS (ttm) | -2.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,596 |
| Open | 4.00 |
| Previous Close | 4.02 |
| Day's Range | 3.96 - 4.32 |
| 52-Week Range | 3.96 - 18.95 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 19.50 (+383.9%) |
| Earnings Date | n/a |
About ACHL
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal c...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ACHL stock is "Buy." The 12-month stock price forecast is 19.50, which is an increase of 383.87% from the latest price.
News
Achilles Therapeutics Provides Business Update and Outlook for 2022
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precisi...
-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing-
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating th...
- Conference call and webcast scheduled for today at 8:30am ET / 1:30pm UK - - Conference call and webcast scheduled for today at 8:30am ET / 1:30pm UK -
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T ...
Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM enables di...
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types -
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstra...
LONDON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today delivere...
Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
- Achilles' platform will help support the consortium to address gaps in delivering cell therapies to patients - - Achilles' platform will help support the consortium to address gaps in delivering cell ...
Achilles Therapeutics to Present at Upcoming Scientific Congresses
LONDON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will present a...
Achilles Therapeutics to Present at Upcoming Investor Conferences
LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
Achilles Therapeutics Announces Grant of US and European Patents
LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...
Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
– Presentations of translational science data at AACR and ASCO illustrate crucial path to potency assay –
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator -
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -
Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference
LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced...
Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Adviso...
LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study a...
LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today present...
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
Achilles Therapeutics Announces Pricing of Initial Public Offering
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...